Syndax Pharmaceuticals, Inc. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
Syndax Pharmaceuticals, Inc. (SNDX) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of $12.64 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-09.
Discontinued › Cash Flow
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2018-05-09
- Syndax Pharmaceuticals, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2018-03-31 was $12.64M, a 14.80% increase year-over-year.
- Syndax Pharmaceuticals, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-12-31 was $1.54M, a 92.76% decline year-over-year.
- Syndax Pharmaceuticals, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-09-30 was $6.92M, a 14.02% decline year-over-year.
- Syndax Pharmaceuticals, Inc. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2017-06-30 was -$36.51M.
- Syndax Pharmaceuticals, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2017 was -$17.03M.
- Syndax Pharmaceuticals, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was -$18.38M.
- Syndax Pharmaceuticals, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$61.67M, a 3366.37% decline from fiscal 2014.
- Syndax Pharmaceuticals, Inc. net cash provided by (used in) investing activities, continuing operations for fiscal 2014 was $1.89M.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month as first filed | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|---|
| 2018-03-31 | $12.64M 10-Q · filed 2018-05-09 | $14.19M derived: sum of 2 quarters · filed 2018-05-09 | $21.11M derived: sum of 3 quarters · filed 2018-05-09 | -$15.40M derived: sum of 4 quarters · filed 2018-05-09 | |
| 2017-12-31 | $1.54M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $8.46M derived: sum of 2 quarters · filed 2018-03-08 | -$28.04M derived: sum of 3 quarters · filed 2018-03-08 | -$17.03M 10-K · filed 2018-03-08 | |
| 2017-09-30 | $6.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$29.59M derived: sum of 2 quarters · filed 2017-11-08 | -$18.57M 10-Q · filed 2017-11-08 | $2.76M derived: sum of 4 quarters · filed 2018-05-09 | |
| 2017-06-30 | -$36.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | -$25.49M 10-Q · filed 2017-08-10 | -$4.16M derived: sum of 3 quarters · filed 2018-05-09 | $3.89M derived: sum of 4 quarters · filed 2018-05-09 | |
| 2017-03-31 | $11.01M 10-Q · filed 2018-05-09 | $11.06M 10-Q · filed 2017-05-09 | $32.34M derived: sum of 2 quarters · filed 2018-05-09 | $40.40M derived: sum of 3 quarters · filed 2018-05-09 | $39.77M derived: sum of 4 quarters · filed 2018-05-09 |
| 2016-12-31 | $21.33M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | $29.38M derived: sum of 2 quarters · filed 2018-03-08 | $28.76M derived: sum of 3 quarters · filed 2018-03-08 | -$18.38M 10-K · filed 2018-03-08 | |
| 2016-09-30 | $8.05M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | $7.43M derived: sum of 2 quarters · filed 2017-11-08 | -$39.71M 10-Q · filed 2017-11-08 | -$57.27M derived: sum of 4 quarters · filed 2018-03-08 | |
| 2016-06-30 | -$624.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10 | -$47.76M 10-Q · filed 2017-08-10 | -$65.32M derived: sum of 3 quarters · filed 2018-03-08 | -$72.73M derived: sum of 4 quarters · filed 2018-03-08 | |
| 2016-03-31 | -$47.14M 10-Q · filed 2017-05-09 | -$64.69M derived: sum of 2 quarters · filed 2018-03-08 | -$72.11M derived: sum of 3 quarters · filed 2018-03-08 | -$89.32M derived: sum of 4 quarters · filed 2018-03-08 | |
| 2015-12-31 | -$17.56M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-08 | -$24.97M derived: sum of 2 quarters · filed 2018-03-08 | -$42.19M derived: sum of 3 quarters · filed 2018-03-08 | -$61.67M 10-K · filed 2018-03-08 | |
| 2015-09-30 | -$7.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-14 | -$24.63M derived: sum of 2 quarters · filed 2016-11-14 | -$44.11M 10-Q · filed 2016-11-14 | ||
| 2015-06-30 | -$17.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-15 | -$36.70M 10-Q · filed 2016-08-15 | |||
| 2015-03-31 | -$19.48M 10-Q · filed 2016-05-16 | ||||
| 2014-12-31 | $1.89M 10-K · filed 2017-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |